keyword
MENU ▼
Read by QxMD icon Read
search

Yttrium 90

keyword
https://www.readbyqxmd.com/read/28202430/vespro-an-individual-patient-data-prospective-meta-analysis-of-selective-internal-radiation-therapy-versus-sorafenib-for-advanced-locally-advanced-or-recurrent-hepatocellular-carcinoma-of-the-sarah-and-sirvenib-trials
#1
Val Gebski, Emma Gibbs, Mihir Gandhi, Gilles Chatellier, Aurelia Dinut, Helena Pereira, Pierce Kh Chow, Valérie Vilgrain
BACKGROUND: Untreated advanced hepatocellular carcinoma (HCC) has an overall poor prognosis. Currently there are 2 ongoing prospective randomized controlled trials that are evaluating the efficacy and safety of sorafenib and selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres in patients with advanced HCC. The SorAfenib versus Radioembolisation in Advanced Hepatocellular carcinoma (SARAH; 459 patients) trial is being performed in Europe and the SIRt VErsus SorafeNIB (SIRveNIB; 360 patients) trial in the Asia Pacific region...
February 15, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28197686/pre-therapeutic-factors-for-predicting-survival-after-radioembolization-a-single-center-experience-in-389-patients
#2
K J Paprottka, F Schoeppe, M Ingrisch, J Rübenthaler, N N Sommer, E De Toni, H Ilhan, M Zacherl, A Todica, P M Paprottka
PURPOSE: To determine pre-therapeutic predictive factors for overall survival (OS) after yttrium (Y)-90 radioembolization (RE). METHODS: We retrospectively analyzed the pre-therapeutic characteristics (sex, age, tumor entity, hepatic tumor burden, extrahepatic disease [EHD] and liver function [with focus on bilirubin and cholinesterase level]) of 389 consecutive patients with various refractory liver-dominant tumors (hepatocellular carcinoma [HCC], cholangiocarcinoma [CCC], neuroendocrine tumor [NET], colorectal cancer [CRC] and metastatic breast cancer [MBC]), who received Y-90 radioembolization for predicting survival...
February 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28187357/a-simple-thick-target-for-production-of-89-zr-using-an-11mev-cyclotron
#3
Jeanne M Link, Kenneth A Krohn, Matthew J O'Hara
The growing interest but limited availability of (89)Zr for PET led us to test targets for the (89)Y(p,n) reaction. The goal was an easily constructed target for an 11MeV Siemens cyclotron. Yttrium foils were tested at different thicknesses, angles and currents. A 90° foil tolerated 41µA without damage and produced ~800 MBq/h, >20mCi, an amount adequate for radiochemistry research and human doses in a widely available accelerator. This method should translate to higher energy cyclotrons.
January 30, 2017: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/28182580/internal-dosimetry-with-the-monte-carlo-code-gate-validation-using-the-icrp-icru-female-reference-computational-model
#4
Daphnée Villoing, Sara Marcatili, Marie-Paule Garcia, Manuel Bardiès
The purpose of this work was to validate GATE-based clinical scale absorbed dose calculations in nuclear medicine dosimetry. GATE (version 6.2) and MCNPX (version 2.7.a) were used to derive dosimetric parameters (absorbed fractions, specific absorbed fractions and S-values) for the reference female computational model proposed by the International Commission on Radiological Protection in ICRP report 110. Monoenergetic photons and electrons (from 50 keV to 2 MeV) and four isotopes currently used in nuclear medicine (fluorine-18, lutetium-177, iodine-131 and yttrium-90) were investigated...
March 7, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28154910/value-of-tumor-stiffness-measured-with-mr-elastography-for-assessment-of-response-of-hepatocellular-carcinoma-to-locoregional-therapy
#5
Sonja Gordic, Jad Bou Ayache, Paul Kennedy, Cecilia Besa, Mathilde Wagner, Octavia Bane, Richard L Ehman, Edward Kim, Bachir Taouli
PURPOSE: The aim of the study was to correlate tumor stiffness (TS) measured with MR elastography (MRE) with degree of tumor enhancement and necrosis on contrast-enhanced T1-weighted imaging (CE-T1WI) in hepatocellular carcinomas (HCC) treated with Yttrium-90 radioembolization (RE) or transarterial chemoembolization plus radiofrequency ablation (TACE/RFA). MATERIAL AND METHODS: This retrospective study was IRB-approved and the requirement for informed consent was waived...
February 2, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28132407/single-institution-experience-of-radioembolization-with-yttrium-90-microspheres-for-unresectable-metastatic-neuroendocrine-liver-tumors
#6
Zhongzhi Jia, Ricardo Paz-Fumagalli, Gregory Frey, David M Sella, J Mark McKinney, Weiping Wang
PURPOSE: To assess the effectiveness of yttrium-90 ((90) Y) microspheres for the treatment of unresectable metastatic liver neuroendocrine tumors (NET). METHODS: From February 2006 to September 2015, 36 patients (19 male and 17 female, age, 63.6 ± 9.4 years) who underwent (90) Y therapy for unresectable liver metastases of NET were included and analyzed retrospectively. All patients received a variety of treatments prior to (90) Y therapy. The radiological response, symptoms improvement of carcinoid syndrome, tumor marker changes, complications, side effects/toxicity, survival and factors related to survival were evaluated and analyzed...
January 29, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28121731/differences-in-radiation-activity-between-glass-and-resin-90y-microspheres-in-treating-unresectable-hepatic-cancer
#7
Trent James, Jacqueline Hill, Thomas Fahrbach, Zachary Collins
The purpose of this study was to compare the difference in prescribed radiation activity between glass and resin yttrium-90 (Y) microspheres for radioembolization of unresectable hepatocellular carcinoma (HCC) or liver metastases at a tertiary care teaching institution. The authors performed a retrospective analysis on 126 patients with primary HCC and hepatic metastatic disease from extrahepatic primary cancers who underwent radioembolization with glass or resin particles between 2008 and 2013 at their institution...
March 2017: Health Physics
https://www.readbyqxmd.com/read/28109633/the-american-college-of-radiology-and-the-american-brachytherapy-society-practice-parameter-for-the-performance-of-low-dose-rate-brachytherapy
#8
Akila N Viswanathan, Beth A Erickson, Geoffrey S Ibbott, William Small, Patricia J Eifel
Brachytherapy is the use of radionuclides to treat malignancies or benign conditions by means of a radiation source placed close to or into the tumor or treatment site. This practice parameter refers only to the use of radionuclide brachytherapy. Brachytherapy alone or combined with external beam therapy plays an important role in the management and treatment of patients with cancer. Low-dose-rate (LDR) brachytherapy has traditionally been used for treating prostate, head and neck, breast, cervical, and endometrial cancers as well as obstructive bile duct, esophageal, or bronchial lesions...
January 2017: Brachytherapy
https://www.readbyqxmd.com/read/28105342/five-percent-dextrose-maximizes-dose-delivery-of-yttrium-90-resin-microspheres-and-reduces-rates-of-premature-stasis-compared-to-sterile-water
#9
Mary Ellen Koran, Samantha Stewart, Jennifer C Baker, Andrew J Lipnik, Fil Banovac, Reed A Omary, Daniel B Brown
Resin Yttrium-90 (Y90) microspheres have historically been infused using sterile water (H2O). In 2013, recommendations expanded to allow delivery with 5% dextrose in water (D5W). In this retrospective study, we hypothesized that D5W would improve Y90 delivery with a lower incidence of stasis. We reviewed 190 resin Y90 infusions using H2O (n=137) or D5W (n=53). Y90 dosimetry was calculated using the body surface area method. Infusion was halted if intra-arterial stasis was fluoroscopically identified prior to clearing the vial...
December 2016: Biomedical Reports
https://www.readbyqxmd.com/read/28078375/assessing-intra-arterial-complications-of-planning-and-treatment-angiograms-for-y-90-radioembolization
#10
Osman Ahmed, Mikin V Patel, Abdulrahman Masrani, Bradford Chong, Mohammed Osman, Jordan Tasse, Jayesh Soni, Ulku Cenk Turba, Bulent Arslan
PURPOSE: To report hepatic arterial-related complications encountered during planning and treatment angiograms for radioembolization and understand any potential-associated risk factors. MATERIALS AND METHODS: 518 mapping or treatment angiograms for 180 patients with primary or metastatic disease to the liver treated by Yttrium-90 radioembolization between 2/2010 and 12/2015 were retrospectively reviewed. Intra-procedural complications were recorded per SIR guidelines...
January 11, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28078116/pretreatment-tumor-volume-as-a-prognostic-factor-in-metastatic-colorectal-cancer-treated-with-selective-internal-radiation-to-the-liver-using-yttrium-90-resin-microspheres
#11
Neha Bhooshan, Navesh K Sharma, Shahed Badiyan, Adeel Kaiser, Fred M Moeslein, Young Kwok, Pradip P Amin, Svetlana Kudryasheva, Michael D Chuong
BACKGROUND: Yttrium-90 ((90)Y)-resin microspheres can prolong intrahepatic disease control and improve overall survival (OS) in patients with metastatic colorectal cancer (CRC). Prognostic factors for improved outcomes in patients undergoing selective internal radiation therapy (SIRT) have been studied, but the relationship between pre-SIRT liver tumor volume and outcomes has not well described. METHODS: We retrospectively reviewed the records of patients with metastatic CRC who were treated at our institution with (90)Y-resin microspheres...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28059929/hepatic-progression-free-and-overall-survival-after-regional-therapy-to-the-liver-for-metastatic-melanoma
#12
Andrea M Abbott, Matthew P Doepker, Youngchul Kim, Matthew C Perez, Cassandra Gandle, Kerry L Thomas, Junsung Choi, Ravi Shridhar, Jonathan S Zager
OBJECTIVES: Regional therapy for metastatic melanoma to the liver represents an alternative to systemic therapy. Hepatic progression-free survival (HPFS), progression-free survival (PFS), and overall survival (OS) were evaluated. MATERIALS AND METHODS: A retrospective review of patients with liver metastases from cutaneous or uveal melanoma treated with yttrium-90 (Y90), chemoembolization (CE), or percutaneous hepatic perfusion (PHP) was conducted. RESULTS: Thirty patients (6 Y90, 10 PHP, 12 CE, 1 PHP then Y90, 1 CE then PHP) were included...
January 4, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28047827/su-c-204-01-a-dosimetric-investigation-into-the-effects-of-yttrium-90-radioembolization-on-the-gi-tract-in-vivo-and-histological-analysis-in-an-animal-model
#13
A Pasciak, L Nodit, A Bourgeois, B Paxton, A Arepally, Y Bradley
PURPOSE: In Yttrium-90 (90Y) radioembolization, non-target embolization (NTE) to the stomach or small bowel can result in ulceration, a rare but difficult to manage clinical complication. However, dosimetric thresholds for toxicity to these tissues from radioembolization have never been evaluated in a controlled setting. We performed an analysis of the effect of 90Y radioembolization in a porcine model at different absorbed-dose endpoints. METHODS: Under approval of the University of Tennessee IACUC, 6 female pigs were included in this study...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28047017/su-c-204-07-radiation-therapy-as-a-potential-treatment-for-obesity-initial-data-from-a-preclinical-investigation
#14
A Pasciak, Y Bradley, L Nodit, A Bourgeois, B Paxton, A Arepally
PURPOSE: To evaluate the feasibility of Yttrium-90 (90Y) radionuclide therapy as a potential treatment for obesity in a porcine model. As the only appetite-stimulating hormone, localized targeting of ghrelin-producing X/A cells in the fundus of the stomach using 90Y may reduce serum ghrelin levels and decrease hunger. METHODS: Under approval of the University of Tennessee IACUC, 8 young female pigs aged 12-13 weeks and weighing 21.8-28.1 Kg were included in this study...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28046479/we-ab-bra-05-pet-guided-delivery-quality-evaluation-of-yttrium-90-microsphere-radioembolizaton-for-hepatocellular-carcinoma-patients-the-optimal-sequence-of-radioembolizaton-and-chemoembolization-treatments
#15
M Lin, B Saboury
PURPOSE: Selective-internal-radiation-therapy (SIRT) and transarterial-chemoembolization (TACE) are commonly used for treatment of liver tumors. The use of TACE, which is macroembolic, prior to SIRT may cause hemodynamic changes in tumor vasculature that impair yttrium-90 (90Y) microsphere delivery to the targeted lesions. This work aims to quantify dosimetric tumor coverage using 90Y positron emission tomography (PET) dosimetry after SIRT alone compared to TACE followed by SIRT. METHODS: A total of 40 consecutive hepatocellular carcinoma (HCC) SIRT patients who had a post-SIRT 90Y PET/CT scan were evaluated...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28012419/formulation-and-purification-of-therapeutic-dose-of-90-y-labeled-peptides-some-interesting-radiochemistry-aspects
#16
Rubel Chakravarty, Sudipta Chakraborty, Ashutosh Dash
Yttrium-90 obtained from most of the (90)Sr/(90)Y generators contains (90)Sr impurity above permissible limit for human administration. A protocol has been optimized for formulation of therapeutic dose of (90)Y-DOTA-Tyr(3)-octreotate ((90)Y-DOTA-TATE) and removal of (90)Sr impurity from it. The radiochemical purity of (90)Y-DOTA-TATE was found to be >98% and it met the requirements for clinical use. The radiopharmaceutical was used in preliminary clinical investigation in patients with neuroendocrine tumors...
March 2017: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/28004357/yttrium-90-radioembolization-for-colorectal-cancer-liver-metastases-a-prospective-cohort-study-on-circulating-angiogenic-factors-and-treatment-response
#17
C E N M Rosenbaum, A F van den Hoven, M N G J A Braat, M Koopman, M G E H Lam, B A Zonnenberg, H M Verkooijen, M A A J van den Bosch
BACKGROUND: Yttrium-90 radioembolization ((90)Y-RE) as a treatment for liver tumours induces radiation damage and hypoxia in liver tissue, which is also a trigger for systemic release of angiogenic factors, potentially stimulating tumour growth. We examined changes in circulating angiogenic factors following (90)Y-RE and investigated the association between response and angiogenic factors. In this prospective study, 42 patients with unresectable, chemorefractory metastatic colorectal cancer (CRCLM) were treated with (90)Y-RE...
December 2016: EJNMMI Research
https://www.readbyqxmd.com/read/28004119/yttrium-90-radioembolization-for-colorectal-cancer-liver-metastases-in-kras-wild-type-and-mutant-patients-clinical-and-ccfdna-studies
#18
E Janowski, O Timofeeva, S Chasovskikh, M Goldberg, A Kim, F Banovac, D Pang, A Dritschilo, K Unger
Patients with unresectable, chemo-refractory colorectal cancer liver metastases (CRCLM) have limited local treatment options. We report our institutional experience on the efficacy of resin-based yttrium-90 (90Y) radioembolization for the treatment of CRCLM and our findings on associated circulating cell-free DNA (ccfDNA) studies. A total of 58 patients treated with 90Y for CRCLM at the Medstar Georgetown University Hospital had a median survival of 6 months [95% confidence interval (CI), 4.55‑7.45 months] after treatment, with a 12-month survival rate of 33%...
January 2017: Oncology Reports
https://www.readbyqxmd.com/read/27996311/evaluating-the-application-of-tissue-specific-dose-kernels-instead-of-water-dose-kernels-in-internal-dosimetry-a-monte-carlo-study
#19
Maryam Khazaee Moghadam, Alireza Kamali Asl, Parham Geramifar, Habib Zaidi
PURPOSE: The aim of this work is to evaluate the application of tissue-specific dose kernels instead of water dose kernels to improve the accuracy of patient-specific dosimetry by taking tissue heterogeneities into consideration. MATERIALS AND METHODS: Tissue-specific dose point kernels (DPKs) and dose voxel kernels (DVKs) for yttrium-90 ((90)Y), lutetium-177 ((177)Lu), and phosphorus-32 ((32)P) are calculated using the Monte Carlo (MC) simulation code GATE (version 7)...
December 2016: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/27957721/computational-simulation-of-the-predicted-dosimetric-impact-of-adjuvant-yttrium-90-pet-ct-guided-percutaneous-ablation-following-radioembolization
#20
Alexander S Pasciak, Abigail Lin, Christos Georgiades, Laura K Findeiss, Shannon Kauffman, Yong C Bradley
BACKGROUND: (90)Y PET/CT post-radioembolization imaging has demonstrated that the distribution of (90)Y in a tumor can be non-uniform. Using computational modeling, we predicted the dosimetric impact of post-treatment (90)Y PET/CT-guided percutaneous ablation of the portions of a tumor receiving the lowest absorbed dose. A cohort of fourteen patients with non-resectable liver cancer previously treated using (90)Y radioembolization were included in this retrospective study. Each patient exhibited potentially under-treated areas of tumor following treatment based on quantitative (90)Y PET/CT...
December 2016: EJNMMI Research
keyword
keyword
8545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"